AMAG Pharmaceuticals Inc.

AMAG Pharmaceuticals Inc.

AMAG Pharmaceuticals Inc. Securities Settlement

The lawsuit was settled for $3.75 million in cash. The following is a summary of the proceedings in this lawsuit: ‘This Action alleges that AMAG, certain of its executives, and a group of underwriters violated the federal securities laws by omitting material facts from the Registration Statement and Prospectus AMAG filed with the Securities and Exchange Commission in connection with the January 21, 2010 Offering, including facts necessary to make the statements therein not misleading. These allegedly omitted facts primarily relate to severe adverse events reported by patients who received AMAG pharmaceutical drug, Feraheme. The Action alleges that as a result of the alleged omissions, Lead Plaintiffs purchased securities whose true value was less than their purchase price.’

© copyright 2015, Liquid Claims. All Rights Reserved. www.liquidclaims.com